Combination of mRNA Vaccines and Immune Checkpoint Inhibitors for Cancer Treatment
Bibliographic record
Abstract
Messenger RNA (mRNA) vaccines have emerged as one of the most promising immunotherapies for cancer due to their treatment efficacy, safety profile, and low development costs.Through the mRNA vaccine, cells are instructed to produce proteins associated with specific mutations in tumors, prompting the immune system to identify and attack these mutations.While mRNA vaccines are considered a rising solution in the field of cancer research, monotherapy trials in general have yet to show significant clinical success.Due to tumors' ability to evade detection by the immune system, including impairing immune cell function and developing resistance to drugs, monotherapies are believed to be insufficient to treat multiple types of cancers.As a result, many scientists have shifted their strategies to prioritize the concept of combination therapy in order to maximize the benefits of clinical trials.The purpose of this paper is to evaluate the potential benefits of combining mRNA vaccines with immune checkpoint inhibitors for cancer treatment.Using data from past clinical trials combining mRNA vaccines with immune checkpoint inhibitors, as well as reviewing trials using immunotherapies alone, we will examine the design and procedures of the trials, as well as the results and data collected.Studies have demonstrated promising results from combining mRNA vaccines with immune checkpoint inhibitors, including improved distant metastasis-free survival (DMFS).These discoveries are vital to opening up a number of new avenues for the treatment of cancers of many types.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".